Levy Adrian R, Kowdley Kris V, Iloeje Uchenna, Tafesse Eskinder, Mukherjee Jayanti, Gish Robert, Bzowej Natalie, Briggs Andrew H
Oxford Outcomes Ltd, Vancouver, BC, Canada.
Value Health. 2008 May-Jun;11(3):527-38. doi: 10.1111/j.1524-4733.2007.00297.x. Epub 2007 Dec 17.
Chronic hepatitis B (CHB) is a condition that results in substantial morbidity and mortality worldwide because of progressive liver damage. Investigators undertaking economic evaluations of new therapeutic agents require estimates of health-related quality of life (HRQOL). Recently, evidence has begun to accumulate that differences in cultural backgrounds have a quantifiable impact on perceptions of health. The objective was to elicit utilities for six health states that occur after infection with the hepatitis B virus from infected and uninfected respondents living in jurisdictions with low and with high CHB endemicity.
Standard gamble utilities were elicited from hepatitis patients and uninfected respondents using an interviewer-administered survey in the United States, Canada, United Kingdom, Spain, Hong Kong, and mainland China. Generalized linear models were used to the effect on utilities of current health, age and sex, jurisdiction and, for infected respondents, current disease state.
The sample included 534 CHB-infected patients and 600 uninfected respondents. CHB and compensated cirrhosis had a moderate impact on HRQOL with utilities ranging from 0.68 to 0.80. Decompensated cirrhosis and hepatocellular carcinoma had a stronger impact with utilities ranging from 0.35 to 0.41. Significant variation was observed between countries, with both types of respondents in mainland China and Hong Kong reporting systematically lower utilities.
Health states related to CHB infection have substantial reductions in HRQOL and the utilities reported in this study provide valuable information for comparing new treatment options. The observed intercountry differences suggest that economic evaluations may benefit from country-specific utility estimates. The extent that systematic intercountry differences in utilities hold true for other infectious and chronic diseases remains an open question and has considerable implications for the proper conduct and interpretation of economic evaluations.
慢性乙型肝炎(CHB)因肝脏进行性损伤,在全球导致了大量的发病和死亡。对新型治疗药物进行经济评估的研究人员需要对健康相关生活质量(HRQOL)进行估计。最近,越来越多的证据表明文化背景差异对健康认知有可量化的影响。目的是从生活在CHB低流行地区和高流行地区的感染和未感染受访者中,获取感染乙型肝炎病毒后出现的六种健康状态的效用值。
通过访员实施的调查,在美国、加拿大、英国、西班牙、中国香港和中国大陆,从肝炎患者和未感染受访者中获取标准博弈效用值。使用广义线性模型研究当前健康状况、年龄、性别、地区以及感染受访者的当前疾病状态对效用值的影响。
样本包括534例CHB感染患者和600例未感染受访者。CHB和代偿期肝硬化对HRQOL有中度影响,效用值范围为0.68至0.80。失代偿期肝硬化和肝细胞癌的影响更强,效用值范围为0.35至0.41。各国之间观察到显著差异,中国大陆和中国香港的两类受访者报告的效用值均系统性较低。
与CHB感染相关的健康状态的HRQOL大幅降低,本研究报告的效用值为比较新的治疗方案提供了有价值的信息。观察到的国家间差异表明,经济评估可能受益于特定国家的效用估计。效用值的系统性国家间差异在其他传染病和慢性病中是否同样存在仍是一个悬而未决的问题,对经济评估的正确实施和解释具有重要意义。